Table 4.

Association of patients and disease characteristics with survival (N = 929)

P
Parameter
No.
Survival at 3 y/5 y, %
Median survival, mo
Log-rank
Cox continuous variable
Age      
    Below 60 y   775   84/71   117   .025   .02  
    At least 60 y   154   88/65   89    
Splenomegaly      
    No   614   87/72   118   .04   —  
    Yes   313   81/66   101    
Hemoglobin      
    Below 120 g/L   356   83/68   103   .32   .11  
    At least 120 g/L   573   86/71   112    
WBC      
    No more than 40 × 109/L   474   85/72   119   .04   .004  
    Above 40 × 109/L   455   85/68   103    
Platelets      
    No more than 450 × 109/L   583   85/71   118   .12   .18  
    Above 450 × 109/L   346   85/68   96    
Peripheral basophils      
    Below 7%   762   86/72   117   < .01   .07  
    At least 7%   166   78/60   76    
Peripheral blasts      
    0%   621   86/72   119   < .01   < .01  
    1% to 3%   257   83/69   103    
    At least 4   50   81/46   58    
Marrow basophils      
    Below 4%   715   87/73   118   < .01   < .01  
    At least 4%   210   80/61   79    
Marrow blasts      
    Below 5%   862   86/70   112   .26   .05  
    At least 5%   63   78/66   118    
Cytogenetic clonal evolution      
    No   872   85/70   111   .30   —  
    Yes   56   76/66   94    
Sokal risk      
    Low   604   87/75   131   < .01   —  
    Intermediate   229   83/65   96    
    High   93   76/50   58    
Hasford risk      
    Low   565   85/73   123   .05   —  
    Intermediate   288   87/69   95    
    High   32   81/52   60    
Duration of chronic phase      
    0 to 3 mo   733   86/73   122   < .01   .002  
    At least 4 mo   196   81/61   96    
Study group      
    Imatinib mesylate   279   96/88   NR   < .01   —  
    IFN-α   650   81/65   101    
Dose of imatinib mesylate      
    400 mg/d   73   93/85   NR   .72   —  
    600 mg/d   12   100/90   NR    
800 mg/d
 		 194
 		 97/96
 		 NR
 
 
 
P
Parameter
No.
Survival at 3 y/5 y, %
Median survival, mo
Log-rank
Cox continuous variable
Age      
    Below 60 y   775   84/71   117   .025   .02  
    At least 60 y   154   88/65   89    
Splenomegaly      
    No   614   87/72   118   .04   —  
    Yes   313   81/66   101    
Hemoglobin      
    Below 120 g/L   356   83/68   103   .32   .11  
    At least 120 g/L   573   86/71   112    
WBC      
    No more than 40 × 109/L   474   85/72   119   .04   .004  
    Above 40 × 109/L   455   85/68   103    
Platelets      
    No more than 450 × 109/L   583   85/71   118   .12   .18  
    Above 450 × 109/L   346   85/68   96    
Peripheral basophils      
    Below 7%   762   86/72   117   < .01   .07  
    At least 7%   166   78/60   76    
Peripheral blasts      
    0%   621   86/72   119   < .01   < .01  
    1% to 3%   257   83/69   103    
    At least 4   50   81/46   58    
Marrow basophils      
    Below 4%   715   87/73   118   < .01   < .01  
    At least 4%   210   80/61   79    
Marrow blasts      
    Below 5%   862   86/70   112   .26   .05  
    At least 5%   63   78/66   118    
Cytogenetic clonal evolution      
    No   872   85/70   111   .30   —  
    Yes   56   76/66   94    
Sokal risk      
    Low   604   87/75   131   < .01   —  
    Intermediate   229   83/65   96    
    High   93   76/50   58    
Hasford risk      
    Low   565   85/73   123   .05   —  
    Intermediate   288   87/69   95    
    High   32   81/52   60    
Duration of chronic phase      
    0 to 3 mo   733   86/73   122   < .01   .002  
    At least 4 mo   196   81/61   96    
Study group      
    Imatinib mesylate   279   96/88   NR   < .01   —  
    IFN-α   650   81/65   101    
Dose of imatinib mesylate      
    400 mg/d   73   93/85   NR   .72   —  
    600 mg/d   12   100/90   NR    
800 mg/d
 		 194
 		 97/96
 		 NR
 
 
 

NR indicates not reached; —, categorical value (P value not applicable).

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal